Background: Liver biopsy and virological end points are standard references for assessing the effect of viral hepatitis treatments. We aimed to review evidence-based published data of biomarkers that have been validated as non-invasive alternatives to biopsy as end points for HBV and HCV infection trials. Methods: Studies were included if there were at least two repeated estimates of fibrosis per patient using biomarkers with at least two studies and a control group. Meta-analysis of the percentage of fibrosis progression per year (pFPy) was performed. Results: Two biomarkers were included, FibroTest® and liver stiffness measurement (LSM; FibroScan®). A total of 1,413 patients with chronic hepatitis C (11 populations) and 772 with chronic hepatitis B (6 populations) were analysed. In a comparison of HCV patients with controls, the FibroTest® pFPy was -18% (95% confidence interval
Infection with HCV or HBV is a major cause of chronic liver disease, affecting 500 million people worldwide [1] [2] [3] [4] . The adverse effects of chronic hepatitis C and B on the liver is mainly because of fibrosis progression, which could result in cirrhosis, liver failure, hepatocellular carcinoma, liver transplantation and death [5] .
The goal of therapy is to prevent complications and death from chronic viral hepatitis [2, 4] . Because of the slow evolution of chronic hepatitis over several decades, it has been difficult to demonstrate that therapy prevents complications of liver disease. Accordingly, treatment responses are defined by surrogate biological parameters rather than by clinical end points [2, 4] .
Short-term outcomes can be measured biochemically (normalization of serum alanine aminotransferase
[ALT] levels), virologically (absence of HCV RNA or HBV DNA from serum by a sensitive PCR-based assay) and histologically (using liver biopsy with a scoring system, that is, ≥2 points improvement in the necroinflammatory Ishak score or 1 point in the Metavir score with no worsening of fibrosis score). Histological and virological end points are accepted by health authorities as short-term outcomes and have been used for approval of new drugs both for hepatitis C [6, 7] and B [8] [9] [10] .
Because of the limitations of liver biopsy (mainly sampling error and risk), several non-invasive biomarkers have recently been validated as alternatives for fibrosis staging, with diagnostic and prognostic values that are similar to those of biopsy [11, 12] . These biomarkers are now widely used in countries where they are available [13] . 
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Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies
Introduction
Very few guidelines have thus far introduced these non-invasive biomarkers as alternatives to biopsy, as end points for clinical trials or as part of routine treatment [14] . In 2006 in France, FibroTest ® and FibroScan ® were validated and recommended by the health authorities as first-line diagnostic procedures for fibrosis or cirrhosis in adults with chronic hepatitis C without previous treatment [15, 16] . The European Medicines Agency has introduced the possibility of using biomarkers in the guidelines 'On the clinical evaluation of direct acting antiviral agents intended for treatment of chronic hepatitis C' [17] , only for the following inclusion criteria: the main role of a histology assessment is to exclude patients with advanced fibrosis and to enable stratification by degree of fibrosis. For this purpose a liver biopsy of adequate quality within 12 months prior to study entry may be employed. If non-invasive methods are used as an alternative to liver biopsy this should be justified by the applicant [17] .
The aim of this study was to review the evidencebased published data of these biomarkers as alternatives to liver biopsy in HBV and HCV trials.
Methods
Inclusion and exclusion criteria
Studies were included if they fulfilled the following criteria: assessment of a fibrosis biomarker previously validated versus biopsy, at least two published studies, paired assessment before and after treatment and at least one control population with paired assessment in the absence of antiviral treatment.
Search strategy
The literature was reviewed using Medline with the following tags: 'paired liver biomarkers', 'biomarkers liver injury HBV', 'biomarkers liver injury HCV', 'liver fibrosis biomarkers HCV', 'liver fibrosis biomarkers HBV', 'liver trials stiffness' and 'liver trials fibrosis biomarkers'. References of previously published reviews, meta-analyses and guidelines were also used [11, 12, [14] [15] [16] [18] [19] [20] [21] [22] [23] [24] [25] [26] .
Fibrosis progression estimates
To standardize the fibrosis progression estimates between biomarkers, the criterion used was the percentage of fibrosis progression per year (pFPy). The definition of pFPy was the ratio of the difference between the second and the first assessment divided by the first assessment, standardized for 1 year between two assessments. For example, for a patient with a first FibroTest ® of 0.60 and a second FibroTest ® of 0.30 2 years later, the pFPy was (0.30-0.60= -0.30)/0.60=-0.50 for 2 years, that is, -25% per year.
Similarly, in FibroScan ® trials, for a patient with a first liver stiffness measurement (LSM) of 12 kPa and a second measurement 2 years later of 6 kPa, the pFPy was equal to ( [6] [7] [8] [9] [10] [11] [12] /12)/2=-25%.
The overall effect of treatment on biomarkers was assessed using a meta-analysis of the difference between the pFPy in treated versus control patients. To demonstrate the accuracy of the biomarkers, the effect on these biomarkers was assessed separately in patients with and without virological response. A few studies in patients with chronic hepatitis C did not provide details between relapsers and non-responders; therefore, the main analysis focused on sustained virological responders (SVR) versus non-responders after exclusion of relapsers. A sensitivity analysis was also performed after inclusion of relapsers. When no control group was available in a study, the mean pFPy of the larger biomarker control group was used.
Because patients were seen decades after the infection, baseline fibrosis stage has been demonstrated as the major predictive factor of fibrosis progression both in chronic hepatitis C and B [11, 12, 14, 24, 27] . When available, the pFPy was calculated separately in patients with and without baseline advanced fibrosis. Advanced fibrosis was defined as bridging fibrosis or cirrhosis (Metavir fibrosis score of ≥2).
We also assessed the transition rate between stages defined as fibrosis stages using Metavir scoring system and the previously defined cutoffs for FibroTest ® 
Sensitivity analyses
For HBV studies, we used another 'response' definition to take into account the specificity of each drug. For lamivudine, which is more powerful than adefovir but has mutations at 2 years, we defined response as the absence of mutations; for adefovir, which has a less rapid effectiveness on viral load but induces less mutations at 1 year, we defined response as a decrease of 3 log 10 IU/ml versus baseline viral load.
Because of the risk of bias from populations without control groups, a sensitivity analysis was performed using only studies with their own controls. In patients with HBV, the disease spectrum was heterogeneous, as patients could include those with spontaneous clearance of HBV surface antigen. A sensitivity analysis was performed after exclusion of controls with spontaneous improvement.
Virological response was defined in HCV patients using the standard definition of responders (sustained virological response, a negative HCV RNA status by PCR at the end of the treatment and after the end of follow-up, non-response and relapse, if available). In patients with chronic hepatitis B, virological response was defined as the absence of detectable HBV DNA at the end of the follow-up.
Meta-analysis
To compare the use of biomarkers as alternatives to biopsy as end points in trials assessing the anti-fibrotic effect of treatment, the pFPy estimated using biomarkers was compared using a meta-analysis, with the hypothesis of a null difference in patients with baseline advanced fibrosis who had both paired estimates.
Necroinflammatory activity grade has been observed to be a factor of variability associated with LSM measurements. To estimate the specificity of a given fibrosis biomarker independent of activity Data used in modelling were individual data when available, or those extracted from publications using means and standard deviations. When these data were not present or were unclear, the authors were contacted.
Statistical analyses
The pFPy were expressed as means and standard deviations and compared using Student's t-test, MannWhitney U test and meta-analyses. Meta-analysis used a random effect model with Cochran's Q heterogeneity test (Q) and Number Cruncher Statistical Systems statistical software (Kaysville, UT, USA) [28] .
Results
Characteristics of studies and patients included
From a total of 1,037 publications, two biomarkers satisfied the inclusion criteria: FibroTest ® and LSM (FibroScan ® ; Figure 1 ). A total of 1,413 patients with chronic hepatitis C (11 populations in 8 published studies) were analysed [29] [30] [31] [32] [33] [34] [35] [36] . The main characteristics are given in Table 1 . FibroTest ® was analysed in nine populations and FibroScan ® in four; in two populations, one treated and one control, both biomarkers were assessed simultaneously [30] .
A total of 772 patients with chronic hepatitis B (six populations in four published studies) were analysed [36] [37] [38] [39] . The main characteristics are given in Table 1 . FibroTest ® and FibroScan ® were each analysed in three populations.
Effect of HCV treatment on fibrosis biomarkers according to virological response
The effect of HCV treatment on biomarkers according to virological response is detailed per population study in Table 2 and Figure 2A for FibroTest ® and in Figure 2B for FibroScan ® . Three studies included control groups with a total of 336 patients. The metaanalysis could not be stratified according to baseline fibrosis stage as no details were given for the main control group [30] . The meta-analysis of the treatment effect versus control assessed with FibroTest ® is given in Figure 2A . In comparison with controls, the mean pFPy was -18% (95% confidence interval [CI] -23--14; P<0.001) in treated patients. There was a lower progression rate in SVR (-27% [95% CI -32--22]) versus non-responders (-10% [95% CI -13--7]; P=0.01]). Significant differences were also observed versus relapsers (Additional file 1). All these FibroTest ® progression rates in treated patients were significantly lower than in control groups. In the sensitivity analysis, when only populations with their own controls were included [29, 30] , the results were similar for the mean decrease in pFPy: -21% (95% CI -30--11; P<0.001) for SVR and -9% (95% CI -16--1; P=0.02) for non-responders.
The meta-analysis of the treatment effect versus control assessed with FibroScan ® is given in Figure 2B . The mean progression rate was reduced by 15% (95% CI -28--1) in comparison with controls (P=0.01). There was a lower progression rate in SVRs (-26% [95% CI -29--23]) versus non-responders (0% [95% CI -12-12]; P=0.01). The two populations had their own controls.
Effect of HBV treatment on fibrosis biomarkers according to virological response
The effect of HBV treatment on biomarkers according to baseline fibrosis stage and to virological response is detailed per population study in Tables 3, 4 and 5. Similar results were observed when non-response was defined according to 3 log 10 IU/ml viral load decrease versus baseline or absence of lamivudine mutation (Additional File 2). No meta-analysis was possible for FibroScan ® as there were no control patients with active chronic hepatitis B. The non-treated patients were inactive carriers or patients with flares [40] .
The meta-analysis of HBV treatment effect versus control assessed with FibroTest ® is given in Figure 2C . In comparison with controls, the mean progression rate per year in treated patients was -6% (95% CI -16-3; P=0.33; without heterogeneity P=0.62).
The meta-analysis could be stratified according to baseline fibrosis score and virological response in all the studies. There was a significant decrease of the pFPy only in patients with baseline advanced fibrosis (mean difference -5% [95% CI -10--0.1]; P=0.02; without heterogeneity Q=1.7 P=0.64; Figure 2D ).
When only populations with their own controls were included [38] , the results were similar to the overall population, with a significant decrease in the pFPy in patients with advanced baseline fibrosis, -19% (95% CI -30--11; P<0.001) for responders and -9% for nonresponders (95% CI -16--1; P=0.02).
Concordance between fibrosis index and fibrosis stage variations
There was significant concordance between FibroTest ® and histological fibrosis stage variations in all included [32, 33, 36] and one in HBV [38] . The results of each of these trials would have been similar for fibrosis end points if FibroTest ® or biopsy had been chosen as the main end point ( Table 6 ). The results would have also been similar for necroinflammatory end points if ActiTest ® or biopsy had been chosen as the main end point (TP, data not shown). Using meta-analysis in patients with advanced baseline fibrosis stratified by disease and virological response, there was no significant difference between the pFPy as estimated either using FibroTest ® or the histological fibrosis scoring system, both in patients with chronic hepatitis C and B (Figure 3 ).
HCV trials
There was no significant mean difference in the pFPy as estimated either with FibroTest ® or biopsy (-5.25% [95% CI -10.98-0.47]; P=0.07; without heterogeneity P=0.97; Figure 3 ) [32, 33] .
In the third study, no direct correlation was detailed between histological and non-invasive estimates of fibrosis [36] . Biomarkers (including FibroTest ® but not Hepascore) were found to be significantly decreased between baseline and end of follow-up in SVR patients with histological liver fibrosis improvement.
HBV trial
There was no significant mean difference in pFPy as estimated either with FibroTest ® or biopsy (-2.10% [95% CI -4.89-0.70]; P=0.14; without heterogeneity P=0.54; Figure 3 ) [32, 33] .
Difference between treatment effect on fibrosis and activity biomarkers
Two studies assessed both fibrosis and necroinflammatory activity using FibroTest ® and ActiTest ® , respectively, in patients with baseline advanced fibrosis and virological response. One was performed in patients with chronic (Table 7) . In both studies, there was a significant and rapid decrease in activity and a delayed effect on fibrosis biomarkers. The decrease in fibrosis biomarkers was not simultaneous with the decrease in activity biomarkers, occurring later and at a significantly lower magnitude (Table 6) . Similarly, FibroTest ® decreased between baseline and end of follow-up in SVR patients in the study of coinfected HCV-HIV patients, regardless of the necroinflammatory activity decrease between paired biopsies [36] .
For FibroScan ® , 13 untreated HBV-infected patients with transaminases flares in one included study had repeated LSM and ALT assays, which is a classical marker of necroinflammatory activity [40] . During flares, LSM values increased from 1.2-to 4.4-fold compared with baseline values (mean variation 2.1-±1.0-fold), with the mean LSM value during flares being 20.7 ±12.3 kPa (range 8.6-42). LSM variations paralleled the dynamic profiles of ALT.
Discussion
This meta-analysis identified two biomarkers (FibroTest ® and FibroScan ® ), which were used in hepatitis trials with at least one control group to assess the effect of antiviral treatment on fibrosis progression.
The evidence-based data suggest that these two biomarkers could be used as non-invasive alternatives to biopsy for estimating the effect of HCV or HBV treatments on fibrosis stage. FibroTest ® and LSM were significantly reduced in virological responders compared with baseline values and compared with virological non-responders. When paired biopsies were available, the same effect was observed with these biomarkers and biopsy, both in responders and non-responders.
This meta-analysis has several weaknesses. The main weakness is the relatively limited number of studies and patients, with most studies published by the same group. However, these data, with repeated measurements, confirm the accuracy of these biomarkers, which have already been extensively validated, including independent validations, in baseline studies versus biopsy [11] [12] [13] [14] [15] [16] 18, 19, 21, 23] . Another expected weakness is the absence of ideal controls. In treatmentnaive patients with advanced fibrosis, follow-up without treatment is unethical. In patients with chronic hepatitis C there were no randomized controls on placebo; however, there was no significant heterogeneity among controls and among treatment effects despite less severe disease in controls. The change in liver histology has been expressed as the difference between Table 7 . Dynamic of fibrosis and activity biomarkers during treatment in virological responders with advanced baseline fibrosis fibrosis scores. There is no perfect histological estimate of fibrosis progression. Metavir is a semiquantitative estimate of fibrosis area and a semiquantitative estimate of mortality and morbidity widely used in modelling [27, [41] [42] [43] . In chronic hepatitis B trials, as observed for repeated biopsy reviews [24] , the heterogeneity of controls was a major cause of variability in the results. The natural history of chronic hepatitis B is very heterogeneous, with a higher prevalence of spontaneous virological improvement than in patients with chronic hepatitis C, resulting in regression of fibrosis in control groups.
Comparison between FibroTest® and FibroScan®
Only one study directly compared repeated measurements of fibrosis by FibroTest ® or FibroScan ® in both treated and non-treated patients with chronic hepatitis C [30] . Expressed as the pFPy, the effect in SVR was higher as assessed by LSM (-23%) than by FibroTest ® (-13%), this was also observed in indirect comparisons (Table 2 ). It is possible that a proportion of the decrease of the pFPy is related to the concomitant effect on necroinflammatory activity. LSM is highly sensitive to necroinflammatory activity [40, 44] , both in chronic hepatitis C and B; therefore, to prevent overestimation by LSM of the antifibrotic effect of antiviral treatments, it is mandatory to consider the simultaneous effect of treatment on activity. One method is to compare the dynamics of a specific activity biomarker with the dynamics of LSM during and after treatment, as performed for FibroTest ® and ActiTest ® [34, 38] (Table 6 ). Histological fibrosis variations are less rapid than necroinflammatory features and a very rapid decrease in a fibrosis marker suggests a lack of specificity.
One possible weakness of FibroTest ® in patients treated with ribavirin is the risk of false-positives caused by haemolysis, which interferes with two components of the panel: total bilirubin and haptoglobin. However, among patients with rapid haemolysis (defined as a decrease of ≥3 g/l), there was no significant difference compared with patients without haemolysis for the FibroTest ® values during and after treatment by standard doses of ribavirin and pegylated interferon [34] .
Comparison with other fibrosis biomarkers
A total of 14 validated biomarkers (with at least two published validations) were identified between 1991 and 2008 [11, 12] . Of them, nine were not patented: PGA index, AP index, Bonacini index, Pohl score, Forn's index, APRI index, MP3 index, FIB4 and FibroIndex; five were patented: FibroTest ® , FibroSpect II, ELF, FibroMeter and Hepascore. Only FibroTest ® had had at least two studies and a control group with repeated measurements for inclusion in a metaanalysis.
In the present meta-analysis, one trial observed that repeated FibroTest ® assessments had better concordance with virological response than the APRI index [35] . Concerning 'baseline studies', meta-analyses have observed higher accuracy for the diagnosis of advanced fibrosis and prognostic value of FibroTest ® versus the APRI index in patients with chronic hepatitis C [29, 45] . In patients with chronic hepatitis B, FibroTest ® also had a higher prognostic value than the APRI [37] . A major weakness of fibrosis biomarkers that include transaminases in their panels (such as APRI, FIB4 or Fibro Meter) is overestimation of the antifibrotic effect of treatment because of the decrease of activity compared with biomarkers without transaminases. Studies using the APRI as a surrogate marker of disease severity should take this lack of specificity into account [45, 46] .
Isolated serum fibrosis markers have a lower accuracy for the diagnosis of fibrosis than panels [11, [14] [15] [16] 32, 47] . Serum levels of YKL-40, a tissue inhibitor of matrix metalloproteinase-1, aminoterminal peptide of type III procollagen (PIIINP) and hyaluronic acid were determined during the lead-in treatment phase of patients enrolled in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial. A statistically significant reduction in levels of these markers was observed at week 72 compared with baseline in the 81 patients with a sustained virological response, but not in the 72 patients with breakthrough or relapse. Use of these markers as alternatives to biopsy in trials was difficult because during treatment with standard pegylated interferon and ribavirin, YKL-40 levels were unchanged in full responders and significant increases were observed in serum PIIINP and hyaluronic acid levels compared with baseline, both in virological responders and nonresponders at weeks 24 and 48 [48] .
Are these evidence-based data sufficient for replacing biopsy with biomarkers in hepatitis trials?
The aim of the present meta-analysis was to identify which biomarker demonstrated its accuracy for assessing liver fibrosis progression during and after antiviral treatment compared with liver biopsy estimates using repeated assessments.
We did not seek to identify biomarkers with this study that were similar to biopsy for two recommended properties: exclusion of patients with advanced fibrosis from participation in early clinical trials and for the stratification of treatment effect, as fibrosis stage is an independent prognostic factor of virological response (in hepatitis C) [17] . From published data, we believe that these two properties have already been demonstrated. For the first property, both FibroTest ® and FibroScan ® have demonstrated their high negative predictive values for advanced fibrosis in chronic hepatitis C and FibroTest ® in chronic hepatitis B [11, 12, 19, 21, 23] , including prognostic studies [29, 37] . For the second property, there are also prospective data demonstrating that FibroTest ® in chronic hepatitis C has the same value as histological fibrosis staging for the prediction of sustained virological response, independent of genotype and baseline viral load, in treatment-naive patients [34] and in previous non-responder patients [49] .
Can these results improve the design of maintenance therapy trials in chronic hepatitis C?
In patients without sustained virological response to HCV treatment, there is controversy about the benefit of maintenance therapy [50, 51] . This controversy could, in part, be related to a lack of power of published negative trials using liver biopsy as the end point. From the present overview in paired studies the mean effect of treatment (full dose of interferon or combination of interferon and ribavirin in treatmentnaive patients) on the fibrosis progression rate in virological non-responders was 10% per year compared with controls. The HALT-C study used small doses of interferon alone in previous non-responder patients. The results of this study show that, as anticipated in the power calculations, maintenance therapy cannot halve the progression rate. The present meta-analysis suggests that these power calculations might have been unrealistic; the aim was to reduce the fibrosis progression per year by 50% (6% in controls versus 3% in treated patients). Assuming that small doses of interferon have the same antifibrotic effect as fulldose combination therapy (10% reduction per year in the present meta-analysis), the number of included patients should have multiplied fivefold. Therefore, only a large study including at least 2,500 patients per group for 4 years using biomarkers and clinical end points could demonstrate the efficacy of maintenance therapy on fibrosis progression and related clinical end points. A 10% reduction of fibrosis progression rate can be clinically significant and cost-effective as the mortality related to infection with HCV is still increasing.
Conclusions
The most validated non-invasive markers of liver fibrosis, FibroTest ® and FibroScan ® , have reached a sufficient level of performance to be considered alternatives to liver biopsy in clinical trials. Previous transversal studies have demonstrated their accuracies for the inclusion of patients with chronic hepatitis C and B and for stratification of analysis according to advanced fibrosis.
The present meta-analysis of longitudinal studies with repeated published data in patients with chronic hepatitis C and B, has demonstrated that the treatment effect on fibrosis progression rate was similarly estimated using FibroTest ® or biopsy. The same concordance was observed according to virological response for FibroScan ® , but with a possible overestimation of the fibrosis regression during the first weeks of treatment in virological responders because of the effect of necrosis and inflammation on LSMs.
Further studies must estimate the performance of biomarkers as end points in maintenance therapy trials and as prognostic factors of virological responses.
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